Business · Companies · 2 hrs ago
Johnson & Johnson considers buying Ollin Biosciences for up to $3.4bn
Johnson & Johnson is looking to buy Ollin Biosciences in a potential deal worth up to $3.4bn.
Ollin is a biotechnology company focused on eye disease, according to the available details.
The proposed acquisition is part of a recent surge in biotech deals.
The deal would bring the eye-disease company under the ownership of the drugmaker if completed.
The potential price is as much as $3.4bn, but no lower figure is given.
The acquisition has not been described as completed, and no further steps are specified.
Johnson & Johnson is considering buying Ollin Biosciences for up to $3.4bn.
The potential acquisition is the latest in a glut of deals in the biotechnology sector.
- Who
- Johnson & Johnson and Ollin Biosciences.
- What
- Johnson & Johnson is considering acquiring Ollin Biosciences for up to $3.4bn.
- When
- The report was published on 15 November 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Potential buyer
- Johnson & Johnson
- Potential acquisition target
- Ollin Biosciences
- Maximum potential deal value
- $3.4bn
- Sector context
- A glut of biotechnology deals